Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17 SEK | +2.53% | -2.86% | +9.96% |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
Apr. 17 | Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US | CI |
Sales 2024 * | 617M 56.72M | Sales 2025 * | 773M 71.12M | Capitalization | 571M 52.54M |
---|---|---|---|---|---|
Net income 2024 * | -110M -10.12M | Net income 2025 * | -29M -2.67M | EV / Sales 2024 * | 1.4 x |
Net Debt 2024 * | 290M 26.68M | Net Debt 2025 * | 199M 18.31M | EV / Sales 2025 * | 1 x |
P/E ratio 2024 * |
-5.21
x | P/E ratio 2025 * |
-19.3
x | Employees | 116 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.49% |
Latest transcript on Orexo AB
1 week | -5.26% | ||
Current month | +6.42% | ||
1 month | +12.64% | ||
3 months | +15.94% | ||
6 months | +16.76% | ||
Current year | +7.24% |
Managers | Title | Age | Since |
---|---|---|---|
Nikolaj Sørensen
CEO | Chief Executive Officer | 52 | 11-09-30 |
Fredrik Järrsten
DFI | Director of Finance/CFO | 57 | 22-08-31 |
Edward Kim
CTO | Chief Tech/Sci/R&D Officer | - | 22-10-25 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 19-04-10 | |
James Noble
CHM | Chairman | 65 | 20-04-15 |
Director/Board Member | 62 | 01-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 17 | +2.53% | 7 316 |
24-04-23 | 16.58 | +5.07% | 20,373 |
24-04-22 | 15.78 | -4.48% | 33,396 |
24-04-19 | 16.52 | -3.95% | 25,541 |
24-04-18 | 17.2 | -1.71% | 6,105 |
Delayed Quote Nasdaq Stockholm, April 24, 2024 at 07:55 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+7.24% | 52.77M | |
+11.94% | 9.18B | |
-16.33% | 4.79B | |
+6.40% | 3.97B | |
+26.98% | 3.98B | |
+28.02% | 2.56B | |
-26.55% | 2.29B | |
-25.02% | 2.23B | |
+5.82% | 1.92B | |
-0.50% | 1.64B |
- Stock Market
- Equities
- ORX Stock